Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice
暂无分享,去创建一个
J. Verhoef | M. Poppelier | K. V. van Kessel | B. Benaissa-Trouw | K. Kraaijeveld | L. Tavares | H. Frasa
[1] A. Algra,et al. Escherichia coli in bacteremia: O-acetylated K1 strains appear to be more virulent than non-O-acetylated K1 strains , 1993, Journal of clinical microbiology.
[2] V. Gant,et al. The application of flow cytometry to the study of bacterial responses to antibiotics. , 1993, Journal of medical microbiology.
[3] S. Opal,et al. Choice of bacteria in animal models of sepsis , 1993, Infection and immunity.
[4] A. Cross,et al. Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection , 1993, Infection and immunity.
[5] J. Verhoef,et al. Monoclonal antibodies that detect live salmonellae , 1992, Applied and environmental microbiology.
[6] N. Koles,et al. Lipopolysaccharide heterogeneity in Escherichia coli J5 variants: analysis by flow cytometry. , 1992, The Journal of infectious diseases.
[7] K. Jann,et al. Capsules of Escherichia coli, expression and biological significance. , 1992, Canadian journal of microbiology.
[8] M. A. Martin,et al. Antiendotoxin monoclonal antibodies for gram-negative sepsis: guidelines from the IDSA. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] R. Tarleton,et al. Medium-scale production and purification of monoclonal antibodies in protein-free medium. , 1991, BioTechniques.
[10] I. Mitov,et al. Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid a of bacterial lipopolysaccharides , 1991, Infection.
[11] C. Sprung,et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .
[12] P. Ward,et al. Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1. , 1991, The Journal of infectious diseases.
[13] I. Phillips,et al. Bacteremia due to Escherichia coli: a study of 861 episodes. , 1990, Reviews of infectious diseases.
[14] W. Neill,et al. A comparison of immunoblotting, flow cytometry and ELISA to monitor the binding of anti-lipopolysaccharide monoclonal antibodies. , 1990, Journal of immunological methods.
[15] J. Chia,et al. Fluorescence-activated cell sorter analysis of binding by lipopolysaccharide-specific monoclonal antibodies to gram-negative bacteria. , 1990, The Journal of infectious diseases.
[16] G. Pluschke,et al. Use of hybridoma immunoglobulin switch variants in the analysis of the protective properties of anti-lipopolysaccharide antibodies in Escherichia coli K1 infection. , 1989, Immunology.
[17] A. Cross,et al. Quantitative Relationship between Capsular Content and Killing of K1-Encapsulated Escherichia coli , 1989, Infection and immunity.
[18] P. Courtoy,et al. Staphylococcus aureus phagocytosis. A new cytofluorometric method using FITC and paraformaldehyde. , 1989, Journal of immunological methods.
[19] A. Halstensen,et al. Flow cytometric assay for the measurement of serum opsonins to Neisseria meningitidis serogroup B, serotype 15. , 1989, Journal of immunological methods.
[20] R. Wenzel,et al. The mortality of hospital-acquired bloodstream infections: need for a new vital statistic? , 1988, International journal of epidemiology.
[21] A P Phillips,et al. Limitations of flow cytometry for the specific detection of bacteria in mixed populations. , 1988, Journal of immunological methods.
[22] A. Cross,et al. Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli. , 1986, The Journal of infectious diseases.
[23] M. Achtman,et al. Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1 , 1985, Infection and immunity.
[24] K. Jann,et al. Escherichia coli O18ac antigen: structure of the O-specific polysaccharide moiety , 1984, Infection and immunity.
[25] A. Cross,et al. The importance of the K1 capsule in invasive infections caused by Escherichia coli. , 1984, The Journal of infectious diseases.
[26] M. Achtman,et al. Role of the capsule and the O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing , 1983, Infection and immunity.
[27] O. Laerum,et al. Phagocytosis of Bacteria by Human Leukocytes Measured by Flow Cytometry , 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[28] W. R. Mccabe,et al. Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates. , 1978, The Journal of infectious diseases.
[29] P. Ralph,et al. Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line , 1975, Nature.
[30] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .
[31] S. Opal,et al. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. , 1993, The Journal of infectious diseases.
[32] K. Jann,et al. Structure and biosynthesis of the capsular antigens of Escherichia coli. , 1990, Current topics in microbiology and immunology.
[33] A. Cross,et al. Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. , 1988, The Journal of infectious diseases.
[34] A. Cross,et al. Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli. , 1983, The Journal of infectious diseases.